Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 276,771 | 157,174 | 200,445 | 201,587 | 233,912 |
| Receivables | 780,375 | 799,310 | 800,646 | 788,309 | 752,390 |
| Inventories | 380,259 | 292,972 | 285,280 | 262,584 | 255,809 |
| Other current assets | 83,378 | 93,314 | 113,389 | 91,713 | 107,580 |
| TOTAL | $1,608,662 | $1,444,325 | $1,504,780 | $1,448,355 | $1,439,032 |
| Non-Current Assets | |||||
| PPE Net | 1,639,741 | 1,525,485 | 1,529,640 | 1,494,080 | 1,465,655 |
| Investments And Advances | 243,811 | 301,847 | 300,281 | 293,787 | 311,602 |
| Intangibles | 3,959,096 | 3,770,888 | 3,846,483 | 3,859,746 | 3,805,178 |
| Other Non-Current Assets | 743,690 | 564,462 | 591,197 | 603,471 | 581,304 |
| TOTAL | $6,586,338 | $6,162,682 | $6,267,601 | $6,251,084 | $6,163,739 |
| Total Assets | $8,195,001 | $7,607,007 | $7,772,381 | $7,699,439 | $7,602,770 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 168,937 | 136,341 | 140,204 | 120,004 | 205,915 |
| Accrued Expenses | 441,115 | 422,245 | 411,506 | 397,423 | 416,836 |
| Other current liabilities | 203,210 | 184,745 | 198,517 | 201,739 | 204,575 |
| TOTAL | $1,055,082 | $993,816 | $1,007,623 | $981,392 | $1,091,585 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,647,147 | 2,514,217 | 2,678,472 | 2,743,774 | 2,707,531 |
| Deferred Revenues | 241,820 | 250,485 | 257,396 | 262,226 | 264,259 |
| Other Non-Current Liabilities | 697,279 | 602,271 | 618,904 | 647,289 | 605,298 |
| TOTAL | $3,537,643 | $3,302,430 | $3,507,203 | $3,604,164 | $3,530,107 |
| Total Liabilities | $4,592,725 | $4,296,246 | $4,514,826 | $4,585,556 | $4,621,692 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 51,350 | 51,297 | 51,271 | 51,183 | 50,986 |
| Common Shares | 513 | 514 | 513 | 512 | 509 |
| Retained earnings | 1,887,218 | 1,720,441 | 1,633,052 | 1,536,032 | 1,432,901 |
| Other shareholders' equity | -191,033 | -263,314 | -202,395 | -233,850 | -257,272 |
| TOTAL | $3,602,276 | $3,310,761 | $3,257,555 | $3,113,883 | $2,981,078 |
| Total Liabilities And Equity | $8,195,001 | $7,607,007 | $7,772,381 | $7,699,439 | $7,602,770 |